356 related articles for article (PubMed ID: 26452191)
1. Monoclonal antibodies in myeloma.
Sondergeld P; van de Donk NW; Richardson PG; Plesner T
Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Jelinek T; Hajek R
Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
[TBL] [Abstract][Full Text] [Related]
3. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Schönfeld K; Zuber C; Pinkas J; Häder T; Bernöster K; Uherek C
J Hematol Oncol; 2017 Jan; 10(1):13. PubMed ID: 28077160
[TBL] [Abstract][Full Text] [Related]
4. Emerging antibodies for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
Lonial S
Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
[TBL] [Abstract][Full Text] [Related]
6. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
[TBL] [Abstract][Full Text] [Related]
7. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Magarotto V; Salvini M; Bonello F; Bringhen S; Palumbo A
Leuk Lymphoma; 2016; 57(3):537-56. PubMed ID: 26445358
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
9. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
Kuroda J; Nagoshi H; Shimura Y; Taniwaki M
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of multiple myeloma.
Richardson PG; Lonial S; Jakubowiak AJ; Harousseau JL; Anderson KC
Br J Haematol; 2011 Sep; 154(6):745-54. PubMed ID: 21777223
[TBL] [Abstract][Full Text] [Related]
12. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
Wong SW; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
[TBL] [Abstract][Full Text] [Related]
13. Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
Robak P; Robak T
BioDrugs; 2016 Apr; 30(2):87-93. PubMed ID: 26927803
[TBL] [Abstract][Full Text] [Related]
14. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
16. New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM; Kumar S
Blood Cancer J; 2016 Jul; 6(7):e451. PubMed ID: 27471867
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP; Paba Prada CE; Richardson PG; Longo DL
Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab granted breakthrough drug status.
Laubach JP; Tai YT; Richardson PG; Anderson KC
Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]